Biopharm proponents claim that using plants can offer an easily controllable, safe, and cost-effective method for manufacturing proteins, provided that proper regulatory safeguards are put into place to ensure that no outcrossing can occur. It is also important to note, that the global demand for particular pharmaceutical protein can easily be met from just a few acres of pharma-crop, which can be grown under high containment conditions (e.g. in the greenhouse). Some scientists even think that the term "gardening" is more appropriate than farming. Opponents are concerned that there are too many ways in which contamination of the food supply involved with using staple crops such as beans or rice. Within the United States, Transgenic plants including but not limited to those which produce pharmaceuticals, are regulated by three government agencies which comprise the Coordinated Framework for Regulation of Biotechnology established in 1986. Companies in this industry hope that proteins made from plants can be used to develop treatments for some of the most serious diseases and conditions such as cancer, diabetes, HIV, heart disease, Alzheimer's disease, cystic fibrosis, multiple sclerosis, Hepatitis C, and arthritis, but no such products have as yet been approved. Pharming in mammals There is much debate over the practicality of using plants to produce proteins?" In 2002, ProdiGene was fined $250,000 and ordered by the USDA to pay over $3 million in cleanup costs after allowing a fraction of a bushel of volunteer pharm corn to comingle with the.